Gut and liver

118 treatments and conditions followed through the public trial records. Not medical advice. How a status is set

Treatments and conditions

Gut and liver
Treatment and conditionWhere it standsTrials
AC-101 for colitis, ulcerativePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Adalimumab-800CW + Fluorescence Imaging for inflammatory bowel diseasesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Alginos Oral Suspension for esophagitisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Anaprazole + Rabeprazole placebo for esophagitis, pepticPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
aSMDC for fecal incontinencePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Atezolizumab for fatty liverPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ATG + CliniMACS® TCR α/β Reagent Kit and CliniMACS® CD19 System + Prednisone/Methylprenisolone + Total Body Irradiation + RITUXIMAB + CLOFARABINE + Melphalan + PALIFERMIN for crohn diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Atorvastatin calcium trihydrate for colitis, ulcerativePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
AZD7798 for crohn diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Baclofen for liver diseases, alcoholicTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Berberine ursodeoxycholate for non-alcoholic fatty liver diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
Bevacizumab + atezolizumab for fatty liverPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Bezlotoxumab for colitis, ulcerativePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Bezlotoxumab for crohn diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Blood Sample + Cerebrospinal Fluid (CSF) Sample + Chemotherapy Drug, Cancer - Physician's Choice + Non-Investigational Surgical Resection + Radiotherapy (RT) + Tumor Tissue Sample + Temozolomide for pyloric stenosis, hypertrophicPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Brivekimig for crohn diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Bv+r-chp for pyloric stenosis, hypertrophicTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Cannabidiol for liver cirrhosisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Chemically induced pluripotent stem cells biological Artificial Liver for liver failurePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Combination of Neostigmine and Glycopyrrolate + I-Box by Dynatronics for fecal incontinencePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Combination of Neostigmine and Glycopyrrolate + I-Box by Dynatronics for neurogenic bowelPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Curcumin for gastritis, atrophicPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
CYTARABINE + Azacitidine + Venetoclax for pyloric stenosis, hypertrophicPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Digital Intelligent Tongue-Pressure Biofeedback Resistance Training for deglutition disordersPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Donor Fecal Microbiota Transplantation for irritable bowel syndromePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
DR10624 Injection for non-alcoholic fatty liver diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
DR10624 Injection for pancreatitisTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Duvakitug for colitis, ulcerativePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
ECC0509 for non-alcoholic fatty liver diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ECC0509 + ECC4703 for non-alcoholic fatty liver diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ECC4703 for non-alcoholic fatty liver diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Efruxifermin for non-alcoholic fatty liver diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
EGEN-5784 (genetically engineered porcine liver) + metra® Extracorporeal Liver Cross-Circulation (ELC) system (OrganOx) for acute-on-chronic liver failureTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Empagliflozin for non-alcoholic fatty liver diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Emvistegrast for colitis, ulcerativePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Epidural spinal cord stimulation for neurogenic bowelTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Ex Vivo CRISPR-Cas9 Gene Editing of Donor Liver for fatty liverPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ex Vivo CRISPR-Cas9 Gene Editing of Donor Liver for liver cirrhosisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ex Vivo CRISPR-Cas9 Gene Editing of Donor Liver for liver failurePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ex vivo perfusion of six-gene-edited porcine liver + Multi-drug immunosuppressive therapy for liver failurePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Faecal microbiota transplantation for gastrointestinal hemorrhagePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Faecal microbiota transplantation for hepatitis, alcoholicPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Faecal microbiota transplantation for liver cirrhosisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Fecal Microbial Transplantation for colitis, ulcerativePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Fecal microbiota for colitisTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Fecal Microbiota Transplantation for inflammatory bowel diseasesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Fecal Microbiota Transplantation for irritable bowel syndromePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Fenofibrate for liver cirrhosis, biliaryPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Fenofibrate in Combination With Ursodeoxycholic Acid for liver cirrhosis, biliaryPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Fluconazole for crohn diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Fluorescence Imaging for inflammatory bowel diseasesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
FMT capsule for irritable bowel syndromeTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Food Security Screening & Referral Program for non-alcoholic fatty liver diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Golimumab for colitis, ulcerativePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Guselkumab for colitis, ulcerativePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Guselkumab for crohn diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
H021 Enteric-coated Tablets High-dose Group for crohn diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
H021 Enteric-coated Tablets Low-dose Group for crohn diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
HepaCure for hepatitisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
HepaCure for liver failurePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
High dose Recombinant Trivalent Subunit Rotavirus Vaccine for gastroenteritisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
HSK31679 for non-alcoholic fatty liver diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
HU6 for non-alcoholic fatty liver diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Hydrocortisone for pancreatitisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Indocyanine Green for biliary atresiaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Infliximab for colitisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Infliximab for crohn diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)2
infliximab (IFX) infusion; azathioprine (AZA) caps for crohn diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
infliximab (IFX) placebo infusion; azathioprine (AZA) caps for crohn diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
INT-210 Capsule for colitis, ulcerativePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Intermittent Reduced Calorie Diet (IRCD) for crohn diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
intra-rectal botulinum toxin injections for fecal incontinencePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
JNJ-78934804 for colitis, ulcerativePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
JP-1366 + placebo for non-erosive reflux diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
local co-administration of autologous ADIpose for crohn diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Mandibular advancement Device for gastroesophageal refluxTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Mid dose Recombinant Trivalent Subunit Rotavirus Vaccine for gastroenteritisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Mirikizumab for colitis, ulcerativePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
miRNA Biomarker-Guided Immunosuppression Minimization for liver diseasesTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Norucholic acid for cholangitis, sclerosingTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Obefazimod for colitis, ulcerativePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Obeticholic acid for fatty liverTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
PALI-2108 for colitis, ulcerativePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Pancreatic enzyme capsules for exocrine pancreatic insufficiencyPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Pancreatic enzyme capsules for pancreatitis, acute necrotizingPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Pegargiminase for non-alcoholic fatty liver diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Phentermine-Topiramate for colitis, ulcerativePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
PJ009 for short bowel syndromePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Placebo for crohn diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Placebo-to-match emvistegrast + Emvistegrast for colitis, ulcerativePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
PolyPill for non-alcoholic fatty liver diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Psychotherapy + TRYP-0082 for irritable bowel syndromePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Rabeprazole sodium for gastroesophageal refluxPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Risankizumab for crohn diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Saccharomyces cerevisiae for irritable bowel syndromePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Semaglutide for non-alcoholic fatty liver diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
single FMT for colitis, ulcerativePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
SNP-610 for non-alcoholic fatty liver diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Soy-tomato juice product + Will include a soy-tomato juice product to be consumed during the 4 week intervention phase. A total of about 12 ounces (administered in two small cans) of the juice will be consumed for pancreatitis, chronicPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
SPY001 for colitis, ulcerativePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
SPY001 + SPY002 for colitis, ulcerativePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
SPY001 + SPY003 for colitis, ulcerativePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
SPY002 for colitis, ulcerativePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
SPY002 + SPY003 for colitis, ulcerativePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
SPY003 for colitis, ulcerativePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
Standard Soy Milk for non-alcoholic fatty liver diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Stimulation for blood pressure with stand for neurogenic bowelTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Stimulation for blood pressure without stand for neurogenic bowelTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Stimulation for trunk and core without stand for neurogenic bowelTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Stimulation for trunk or core with stand for neurogenic bowelTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Survodutide for liver diseasesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Survodutide for non-alcoholic fatty liver diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Trametinib + DABRAFENIB for pancreatic diseasesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Transcatheter tricuspid valve replacement for gastroesophageal refluxTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Vedolizumab for colitisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Vedolizumab for colitis, ulcerativePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Vedolizumab for crohn diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Very-low calorie diet for fatty liverTrial registered, as of 19 Nov 2026 (not yet checked by a person)1